Hematopoietic stem cell transplantation (HSCT) is currently the standard of care for many malignant and nonmalignant blood diseases. As several treatment-emerging acute toxicities are expected, optimal supportive measurements critically affect HSCT outcomes. The paucity of good clinical studies in supportive practices gives rise to the establishment of heterogeneous guidelines across the different centers, which hampers direct clinical comparison in multicentric studies. Aiming to harmonize the supportive care provided during the pediatric HSCT in Europe, the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) promoted dedicated workshops during the years 2017 and 2018. The present paper describes the resulting consensus on the management of sinusoidal obstructive syndrome, mucositis, enteral and parenteral nutrition, iron overload, and emesis during HSCT.

Central Hospital of Southern Pest National Institute of Hematology and Infectious Disease Budapest Hungary

Children's Hospital and Pediatric Research Center University of Helsinki Helsinki Finland

Clinica Pediatrica Università degli Studi di Milano Bicocca Fondazione MBBM Ospedale San Gerardo Monza Italy

Department for Children and Adolescents University Hospital Goethe University Frankfurt am Main Germany

Department of BMT Great Ormond Street Hospital for Children National Health Service Foundation Trust London UK

Department of Hematology Immunology Oncology and Stem Cell Transplantation University Children's Hospital Zürich Zürich Switzerland

Department of Paediatric Haematology Oncology Royal Hospital for Children Glasgow Scotland UK

Department of Pediatric Bone Marrow Transplantation Unit MedicalPark Göztepe Hospital Instanbul Turkey

Department of Pediatric Hematology and Oncology Oslo University Hospital Oslo Norway

Department of Pediatric Hematology and Pediatric Stem Cell Transplantation Unit Antalya and Goztepe Medicalpark Hospitals Antalya Turkey

Department of Pediatric Hematology Oncology and BMT Wroclaw Medical University Wroclaw Poland

Department of Pediatric Hematology Oncology and Cell and Gene Therapy IRCCS Ospedale Bambino Gesù Rome Italy

Department of Pediatric Hematology Oncology and Stem Cell Transplantation University Hospital of Regensburg Regensburg Germany

Department of Pediatric Oncology and Hematology Hospital Universitari Vall d'Hebron Barcelona Spain

Department of Pediatric Oncology Hematology and HSCT Poznan University of Medical Sciences Poznań Poland

Department of Pediatrics and Adolescent Medicine Copenhagen University Hospital Rigshospitalet Copenhagen Denmark

Department of Pediatrics Oulu University Hospital Oulu Finland

Department of Pediatrics University Hospital Center Zagreb Zagreb Croatia

Division for Stem Cell Transplantation and Immunology Department for Children and Adolescents University Hospital Goethe University Frankfurt am Main Germany

Division of Molecular Hematology Lund University Lund Sweden

Division of Pediatric Hematology and Oncology Hospital Motol Charles University Prague Czech Republic

Division of Pediatric Hematology Oncology and BMT The Edmond and Lily Safra Children's Hospital Tel Hashomer Israel

Division of Pediatric Hematology Oncology University Children's Hospital of Basel Basel Switzerland

Division of Pediatric Hematology Oncology University Hospital of Geneva Geneva Switzerland

Division of Pediatric Hematoloy Oncology Schneider Children's Medical Center of Israel Petach Tikva Israel

Division of Pediatric Stem Cell Therapy Clinic for Pediatric Oncology Hematology and Clinical Immunology Medical Faculty Heinrich Heine University Duesseldorf Germany

EBMT Paris Office Hôpital Saint Antoine Paris France

Heinrich Heine University Dusseldorf Dusseldorf Germany

Hematology and Immunology Department Robert Debre Hospital Assistance Publique Hopitaux de Paris and University of Paris Paris France

Institute for Transfusion Medicine and Immunohematology of Goethe University and German Red Cross Blood Service Baden Württemberg Hessen Frankfurt Main Germany

Paediatric Haematology Oncology Department IRCCS G Gaslini Genova Italy

Paediatric Transplant Unit Hospital University and Polytechnic Hospital LA FE Valencia Spain

Pediatric Hematology Oncology and HSCT Unit Hospital Santa Creu i Sant Pau Barcelona Spain

Pediatric Hematology Oncology Department of Mother and Child Azienda Ospedaliera Universitaria Integrata Verona Italy

SCT Unit St Anna Children's Hospital Medical University Vienna Vienna Austria

Erratum v

Bone Marrow Transplant. 2020 Jun;55(6):1214. doi: 10.1038/s41409-020-0838-0. PubMed

Zobrazit více v PubMed

Bras G, Hill KR. Veno-occlusive disease of the liver; essential pathology. Lancet. 1956;271:161–3. PubMed

Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53:138–45. PubMed

Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25:1271–80. PubMed

Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51:906–12. PubMed PMC

Faraci M, Bertaina A, Luksch R, Calore E, Lanino E, Saglio F, et al. Sinusoidal obstruction syndrome/veno-occlusive disease after autologous or allogeneic hematopoietic stem cell transplantation in children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group. Biol Blood Marrow Transplant. 2019;25:313–20.

Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:975–81. PubMed

Gharib MI, Bulley SR, Doyle JJ, Wynn RF. Venous occlusive disease in children. Thromb Res. 2006;118:27–38. PubMed

Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol. 2000;64:32–8. PubMed

Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS, et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:137–43. PubMed

Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100:1977–83. PubMed

Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379:1301–9. PubMed

Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163:444–57. PubMed

Al Beihany A, Al Omar H, Sahovic E, Chaudhri N, Al Mohareb F, Al Sharif F, et al. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transplant. 2008;41:287–91. PubMed

Myers KC, Lawrence J, Marsh RA, Davies SM, Jodele S. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2013;19:500–3. PubMed

Qutob AF, Gue S, Revesz T, Logan RM, Keefe D. Prevention of oral mucositis in children receiving cancer therapy: a systematic review and evidence-based analysis. Oral Oncol. 2013;49:102–7. PubMed

Wallhult E, Quinn B. Early and acute complications and the principles of HSCT nursing care. In: Kenyon M, Babic A, editors. The european blood and marrow transplantation textbook for nurses: under the auspices of EBMT. Cham: Springer International Publishing; 2018. p. 163–95.

Tomlinson D, Judd P, Hendershot E, Maloney AM, Sung L. Measurement of oral mucositis in children: a review of the literature. Support Care Cancer. 2007;15:1251–8. PubMed

Quinn B, Potting CM, Stone R, Blijlevens NM, Fliedner M, Margulies A, et al. Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur J Cancer. 2008;44:61–72. PubMed

Ethier MC, Regier DA, Tomlinson D, Judd P, Doyle J, Gassas A, et al. Perspectives toward oral mucositis prevention from parents and health care professionals in pediatric cancer. Support Care Cancer. 2012;20:1771–7. PubMed

Harris DJ, Eilers J, Harriman A, Cashavelly BJ, Maxwell C. Putting evidence into practice: evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs. 2008;12:141–52. PubMed

The modified would be:American Academy of Pediatric Dentistry (AAPD)". Guideline on dental management of pediatric patients receiving chemotherapy, hematopoietic cell transplantation and/or radiation therapy. The reference manual of pediatric dentistry; 37:422–30

Chaveli-Lopez B, Bagan-Sebastian JV. Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent. 2016;8:e201–9. PubMed PMC

Wang L, Gu Z, Zhai R, Zhao S, Luo L, Li D, et al. Efficacy of oral cryotherapy on oral mucositis prevention in patients with hematological malignancies undergoing hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. PLoS ONE. 2015;10:e0128763. PubMed PMC

Treister N, Nieder M, Baggott C, Olson E, Chen L, Dang H, et al. Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation. Br J Cancer. 2017;116:21–7. PubMed

Gobbo M, Verzegnassi F, Ronfani L, Zanon D, Melchionda F, Bagattoni S, et al. Multicenter randomized, double-blind controlled trial to evaluate the efficacy of laser therapy for the treatment of severe oral mucositis induced by chemotherapy in children: laMPO RCT. Pediatr Blood Cancer. 2018;65:e27098. PubMed

Vitale MC, Modaffari C, Decembrino N, Zhou FX, Zecca M, Defabianis P. Preliminary study in a new protocol for the treatment of oral mucositis in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) and chemotherapy (CT). Lasers Med Sci. 2017;32:1423–8. PubMed

Langdana A, Tully N, Molloy E, Bourke B, O’Meara A. Intensive enteral nutrition support in paediatric bone marrow transplantation. Bone Marrow Transplant. 2001;27:741–6. PubMed

Wilken M. The impact of child tube feeding on maternal emotional state and identity: a qualitative meta-analysis. J Pediatr Nurs. 2012;27:248–55. PubMed

Azarnoush S, Bruno B, Beghin L, Guimber D, Nelken B, Yakoub-Agha I, et al. Enteral nutrition: a first option for nutritional support of children following allo-SCT? Bone Marrow Transplant. 2012;47:1191–5. PubMed

Lemal R, Cabrespine A, Pereira B, Combal C, Ravinet A, Hermet E, et al. Could enteral nutrition improve the outcome of patients with haematological malignancies undergoing allogeneic haematopoietic stem cell transplantation? A study protocol for a randomized controlled trial (the NEPHA study). Trials. 2015;16:136. PubMed PMC

Gonzales F, Bruno B, Alarcon Fuentes M, De Berranger E, Guimber D, Behal H, et al. Better early outcome with enteral rather than parenteral nutrition in children undergoing MAC allo-SCT. Clin Nutr. 2018;37:2113–21. PubMed

Rzepecki P, Barzal J, Oborska S. Blood and marrow transplantation and nutritional support. Support Care Cancer. 2010;18:S57–65. PubMed

Seguy D, Duhamel A, Rejeb MB, Gomez E, Buhl ND, Bruno B, et al. Better outcome of patients undergoing enteral tube feeding after myeloablative conditioning for allogeneic stem cell transplantation. Transplantation. 2012;94:287–94. PubMed

Heubi JE. Whenever possible, use the gut! J Pediatr Hematol Oncol. 1999;21:88–90. PubMed

Angelucci E, Pilo F. Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major. Ann N Y Acad Sci. 2016;1368:115–21. PubMed

Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant. 2008;41:997–1003. PubMed

Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17–21. PubMed

Jastaniah W, Harmatz P, Pakbaz Z, Fischer R, Vichinsky E, Walters MC. Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatr Blood Cancer. 2008;50:319–24. PubMed

Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematol Am Soc Hematol Educ Program. 2017;2017:265–71.

Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327–31. PubMed

Wood JC. Use of magnetic resonance imaging to monitor iron overload. Hematol Oncol Clin North Am. 2014;28:747–64. PubMed PMC

Wood JC. Guidelines for quantifying iron overload. Hematol Am Soc Hematol Educ Program. 2014;2014:210–5.

Yesilipek MA, Karasu G, Kaya Z, Kuskonmaz BB, Uygun V, Dag I, et al. A phase II, multicenter, single-arm study to evaluate the safety and efficacy of deferasirox after hematopoietic stem cell transplantation in children with beta-thalassemia major. Biol Blood Marrow Transplant. 2018;24:613–8. PubMed

Mariotti E, Angelucci E, Agostini A, Baronciani D, Sgarbi E, Lucarelli G. Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol. 1998;103:916–21. PubMed

Jarisch A, Salzmann-Manrique E, Cario H, Grosse R, Soerensen J, Fischer R, et al. Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation. Eur J Haematol. 2018;101:791–7. PubMed

Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program. 2009;1:215–21.

Navari RM. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015;1848:2738–46. PubMed

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, et al. NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017;15:883–93. PubMed

Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8:187–98. PubMed

Dupuis LL, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2013;60:1073–82. PubMed

Dupuis LL, Robinson PD, Boodhan S, Holdsworth M, Portwine C, Gibson P, et al. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. Pediatr Blood Cancer. 2014;61:1506–12. PubMed

Dupuis LL, Roscoe JA, Olver I, Aapro M, Molassiotis A. 2016 updated MASCC/ESMO consensus recommendations: anticipatory nausea and vomiting in children and adults receiving chemotherapy. Support Care Cancer. 2017;25:317–21. 2017 PubMed

Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017;25:303–8. 2017 PubMed

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35:3240–61.

Patel P, Robinson PD, Thackray J, Flank J, Holdsworth MT, Gibson P, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Pediatr Blood Cancer. 2017;64:1–12.

Dupuis LL, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57:191–8. PubMed

Morrow GR. Effect of the cognitive hierarchy in the systematic desensitization treatment of anticipatory nausea in cancer patients: a component comparison with relaxation only, counseling, and no treatment. Cogn Ther Res. 1986;10:421–46.

Flank J, Robinson PD, Holdsworth M, Phillips R, Portwine C, Gibson P, et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. Pediatr Blood Cancer. 2016;63:1144–51. PubMed

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol. 2017;83:2148–62. PubMed PMC

Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)